tiprankstipranks
Advertisement
Advertisement

ZNTL Stock Latest News

Zentalis Starts Pivotal Phase 3 ASPENOVA Ovarian Cancer Trial
Company AnnouncementsZentalis Starts Pivotal Phase 3 ASPENOVA Ovarian Cancer Trial
5d ago
8K
ZNTL
Zentalis Highlights New Azenosertib Data in Breast Cancer
PremiumCompany Announcements
Zentalis Highlights New Azenosertib Data in Breast Cancer
23d ago
8K
ZNTL
Zentalis to present azenosertib preclinical data in TNBC at AACR meeting
PremiumThe Fly
Zentalis to present azenosertib preclinical data in TNBC at AACR meeting
23d ago
ZNTL
Midday Fly By: CoreWeave inks Anthropic, TSMC reports March sales bump
PremiumThe Fly
Midday Fly By: CoreWeave inks Anthropic, TSMC reports March sales bump
1M ago
E
MU
Zentalis price target raised to $10 from $6 at Guggenheim
PremiumThe Fly
Zentalis price target raised to $10 from $6 at Guggenheim
1M ago
ZNTL
Zentalis Advances Azenosertib Dose in DENALI Phase 2
PremiumCompany AnnouncementsZentalis Advances Azenosertib Dose in DENALI Phase 2
1M ago
8K
ZNTL
Advancing Azenosertib Pipeline and DENALI Readouts Underpin Buy Rating on Zentalis Pharmaceuticals
Premium
Ratings
Advancing Azenosertib Pipeline and DENALI Readouts Underpin Buy Rating on Zentalis Pharmaceuticals
1M ago
ZNTL
ZNTL Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
ZNTL Earnings this Week: How Will it Perform?
2M ago
ZNTL
Zentalis outlines 2026 milestones for azenosertib program
PremiumCompany Announcements
Zentalis outlines 2026 milestones for azenosertib program
4M ago
8K
ZNTL
Zentalis Pharmaceuticals: Balancing DENALI Momentum and ASPENOVA Visibility Against Pivotal Data and Execution Risk (Hold Rating Maintained)
PremiumRatings
Zentalis Pharmaceuticals: Balancing DENALI Momentum and ASPENOVA Visibility Against Pivotal Data and Execution Risk (Hold Rating Maintained)
4M ago
ZNTL
Zentalis provides update, key milestones in 2025, expectations for 2026
PremiumThe Fly
Zentalis provides update, key milestones in 2025, expectations for 2026
4M ago
ZNTL
Zentalis Pharmaceuticals Announces Stock Repurchase Agreement
PremiumCompany Announcements
Zentalis Pharmaceuticals Announces Stock Repurchase Agreement
5M ago
8K
ZNTL
Zentalis Pharmaceuticals Reports Q3 2025 Financial Results
PremiumCompany AnnouncementsZentalis Pharmaceuticals Reports Q3 2025 Financial Results
6M ago
ZNTL
Zentalis price target lowered to $4 from $8 at Morgan Stanley
Premium
The Fly
Zentalis price target lowered to $4 from $8 at Morgan Stanley
6M ago
ZNTL
Buy Rating for Zentalis Pharmaceuticals Driven by Promising Clinical Progress and Strategic Focus on PROC
Premium
Ratings
Buy Rating for Zentalis Pharmaceuticals Driven by Promising Clinical Progress and Strategic Focus on PROC
6M ago
ZNTL
Zentalis Pharmaceuticals Reports Q3 2025 Financial Results
PremiumCompany Announcements
Zentalis Pharmaceuticals Reports Q3 2025 Financial Results
6M ago
8K
ZNTL
Zentalis reports Q3 EPS (37c), consensus (48c)
PremiumThe Fly
Zentalis reports Q3 EPS (37c), consensus (48c)
6M ago
ZNTL
Strategic Advancements and Promising Developments Drive Buy Rating for Zentalis Pharmaceuticals
PremiumRatings
Strategic Advancements and Promising Developments Drive Buy Rating for Zentalis Pharmaceuticals
7M ago
ZNTL
Zentalis board member Letai frontrunner to lead NCI, STAT reports
PremiumThe Fly
Zentalis board member Letai frontrunner to lead NCI, STAT reports
8M ago
ZNTL
Zentalis Pharmaceuticals Announces New Chief Legal Officer
PremiumCompany AnnouncementsZentalis Pharmaceuticals Announces New Chief Legal Officer
9M ago
8K
ZNTL
Zentalis CLO Andrea Paul to depart, James Bucher to succeed
Premium
The Fly
Zentalis CLO Andrea Paul to depart, James Bucher to succeed
9M ago
ZNTL
Zentalis price target lowered to $5 from $6 at Wells Fargo
Premium
The Fly
Zentalis price target lowered to $5 from $6 at Wells Fargo
9M ago
ZNTL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >